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Objective Desmosomes are intercellular junctions that
confer strong cell–cell adhesion. Two main members of
desmosomal cadherins, desmogleins (DSGs) and
desmocollins (DSCs), are involved in carcinogenesis.
However, their role in human lung cancer remained
elusive. The aims of this study were to analyse the
expression of DSCs and to evaluate their clinical
application in lung cancer.
Methods The expression of DSC1-3 mRNAs was
analysed by RT-PCR. The methylation status of DSCs was
analysed by demethylation tests and bisulphite
sequencing. Protein expression of DSCs in primary lung
cancer was evaluated by immunohistochemistry on
tissue microarrays.
Results DSC1-3 mRNAs were downregulated in lung
cancer cells, and the expression was restored in four out
of seven cell lines, respectively, after 5-aza-20-
deoxycytidine treatment. A heterogeneous methylation
pattern was detected by bisulphite sequencing in exon 1
of DSC2 and DSC3. In 199 patients with primary lung
cancer, we found that lower protein expression of DSC1
was significantly linked to worse tumour differentiation
(p=0.017), DSC3 proteins were more expressed in
squamous cell carcinoma (SCC) compared with
adenocarcinoma (ADC) (p<0.001), and reduced
expression of DSC1 and DSC3 was significantly
correlated with poor clinical outcome (p=0.045 and
p=0.007, respectively).
Conclusions Our data suggest that downregulation of
DSC1-3 may be explained by DNA methylation, DSC1 may
be a marker for tumour differentiation, DSC3 has a potential
diagnostic value in subclassification of non-small cell lung
carcinoma into SCC and ADC, and furthermore, DSC1 and
DSC3 may be prognostic markers for lung cancer.
INTRODUCTION
The desmosomes are intercellular junctions that
act as anchors for intermediate filaments, and they
are crucial to tissues that experience mechanical
stress.1 Desmosomes are made of proteins from
three families: the desmosomal cadherins, the
armadillo family and the plakin family of cytolin-
kers. The cell adhesion proteins of the desmo-
somes, DSGs (DSG1-4) and DSCs (DSC1-3), are
members of the cadherin family.2 DSGs and DSCs
are membrane-spanning glycoproteins that
mediate adhesion by interacting with other family
members on adjacent cells.3 4
The role of desmosomal proteins in cancer devel-
opment and progression is not well understood,
though a body of evidence indicates that they may
influence epithelial cell invasion and metastasis
since an important function of desmosomes related
to cancer is their ability to inhibit cell motility.5 For
example, loss of expression of desmoplakin, a com-
ponent of desmosomal plaque proteins, promotes
increased local tumour invasion in a mouse model
of pancreatic neuroendocrine carcinogenesis;6 loss
of DSC2 contributes to the growth of colorectal
cancer cells by regulating Akt/β-catenin signalling.7
Both tumour-promoting and tumour-suppressive
functions have been assigned to desmosomal pro-
teins.2 For instance, DSG2 was found to be overex-
pressed in skin cancer,8 DSG3 was upregulated in
head and neck cancer as well as lung cancer.9 10 11
By contrast, DSC3 ablation increased the incidence
of Ras-induced skin tumour in mice,12 and further-
more, DSC3 was found to be downregulated in
breast and colorectal cancer due to promoter
hypermethylation.13 14
In a previous study, we performed suppression-
subtractive hybridisation to compare gene expres-
sion between normal human bronchial epithelial
cells (HBEC) and a lung squamous carcinoma cell
line H2170.15 Two cDNA libraries were cloned.
The clone, HBEC-80 with high similarity to des-
mocollin 3, was found in the library enriched for
the genes which were downregulated in tumour
cells. Further investigations revealed that DSC3
plays an important role in lung carcinogenesis (Cui
et al. 2012, in press).
In this study we analysed the expression of
DSC1-3 in human lung cancer and investigated
their clinical relevance.
MATERIALS AND METHODS
Cell lines and cell culture
Human lung carcinoma cell lines, including non-
small cell lung carcinomas (SCC: H157, H226,
H2170; adenocarcinoma (ADC): H23, H2030,
H2228 and H322), and small cell lung carcinomas
(SCLCs: SHP77, CPC-N, H82, COLO677,
COLO668 and H526) were purchased from the
American Type Culture Collection (ATCC,
Rockville, Maryland, USA), and from the German
Collection of Microorganisms and Cell Culture
(DSMZ, Braunschweig, Germany). Cells were
grown in RPMI 1640 medium (BIOCHROM AG,
Germany) supplemented with 10% (v/v) foetal
bovine serum (FBS), and maintained in a humidi-
fied atmosphere with 5% CO2 at 37°C. In addition,
three ADC cell lines including D51, D54 and D117
were established in our laboratory. They were
derived from primary tumours of patients who
were operated at the University Hospital Charité.
These cells were grown in Leibovitz 15 media sup-
plemented with 10% (v/v) FBS and 1% (w/v)
glutamine.
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RNA extraction and RT-PCR
Total RNAwas extracted from the cells using the Trizol reagent
(Invitrogen, Karlsruhe, Germany). One microgram of total
RNA was reverse-transcribed into cDNA using a QuantiTect
Reverse Transcription Kit (Qiagen, Hilden, Germany).
PCR amplification of DSC1-3 was performed under the fol-
lowing conditions: 94°C 1 min, 53°C 30 s, 72°C 30 s, for 35
cycles, with initial denaturation at 95°C 15 min, and final elong-
ation at 72°C 7 min. Glyceraldehyde-3-phosphate dehydrogenase
was used as control. Primer sequences are shown in
supplementary data 1.
Demethylation tests
For demethylation tests, seven lung cancer cell lines were
plated and cultured in 10 cm dishes. At 50% confluence, 10, 20
and 25 mM of 5-aza-20-deoxycytidine (DAC) (Sigma Chemical
Co, St Louis, MO USA) were added to the medium on days 0
and 2. Cells were harvested on day 4 for total RNA isolation.
Bisulphite sequencing
Bisulphite-treated DNA was subjected to PCR amplification.
Two pairs of primers (supplementary data 1) were designed for
amplification of both unmethylated and methylated sequences.
Hot-start PCR (Peqlab, Germany) was carried out to amplify
the CpG sites of DSC2 and DSC3 with the following
conditions: 95°C 15 min, 40 cycles of 95°C 1 min, 60°C 45 s
and 72°C 45 s, with a final extension at 72°C 7 min. PCR
products were applied for direct sequencing by capillary electro-
phoresis (LGC, Berlin, Germany).
Immunohistochemistry
Three hundred and ninety-eight tumour specimens from 199
patients with primary lung cancer were used for the construc-
tion of tissue microarrays (TMAs). All the patients were under-
going surgical operation at the department of surgery of the
Central Hospital Bad Berka GmbH. No adjuvant radiotherapy
or chemotherapy was administered before surgery. The clinico-
pathologic features of the samples are listed in table 1 according
to the WHO/TNM classification of lung cancer.16
TMAs were constructed as previously described.17 All cases
were reviewed on whole sections stained by standard H&E and
AB-PAS alcian blue-periodic acid schiff by two pathologists (M
Mireskandari and T Knösel). Two tissue cylinders per tumour
with a diameter of 0.6 mm were present in one TMA.
A section from the TMAwas dewaxed with xylene and grad-
ually hydrated. Antigen retrieval was performed by treatment
in a pressure cooker for 6 min. The primary antibodies used
were as follows: polyclonal antidesmocollin 1 antibody (Sigma,
USA; 1 : 100), polyclonal antidesmocollin 2 antibody (Acris,
Germany; 1 : 800), and monoclonal antidesmocollin 3 antibody
(Acris, Germany; 1 : 100). Detection took place according to the
manufacturer ’s instructions (LSAB 2-kits, DAKO, Denmark).
All slides were read by two pathologists (M Mireskandari and
T Knösel). Immunohistochemistry was scored semiquantita-
tively as negative (less than 5% cells were stained) and positive
(more than 5% cells were stained).
Statistical analysis
To compare the protein expression of DSC1-3 with clinico-
pathologic parameters, χ2 or Fisher ’s exact test was applied.
Kaplan–Meier survival curves were constructed for statistical
significance with the logrank tests. Cox proportional hazard
analysis was used to quantify the HR of each risk factor, and
forward stepwise multivariable analysis was used to identify
the prognostic factors. All p values were calculated two-sided.
Difference was considered statistically significant when p value
was 0.05 or less. The statistical analysis was performed by
using the software package SPSS 19.0 (SPSS, Chicago, Illinois,
USA).
RESULTS
mRNA expression of DSCs in lung cancer cell lines
RT-PCR showed that mRNA of DSC1-3 was expressed in
human bronchial epithelial cells. DSC1 was expressed in H23,
H226, H2170 and H322, but in other cell lines, there was no
signal detectable. DSC2 was expressed in most of the cell lines
tested, except for two SCLC cell lines CPC-N and COLO677.
DSC3 was only expressed in H226, while silenced in other cell
lines (figure 1A).
Restoration of DSCs mRNA expression by
5-aza-20-deoxycytidine (DAC)
After treatment with different concentrations of the demethyla-
tion agent DAC for 96 h, DSCs mRNA expression was restored
in four out of seven cell lines for DSC1-3, respectively (figure 1B).
In some of the cell lines, the reexpression of DSCs was in a
concentration-dependent manner (eg, DSC1 re-expression in
SHP77, DSC2 re-expression in H157 and COLO677, as well as
DSC3 re-expression in COLO677).
Analysis of DSCs methylation status in lung cancer cell lines
We evaluated the methylation status of DSC2 DNA in 31 CpG
sites and DSC3 DNA in 20 CpG sites (table 2). There was no
CpG island in the promoter region/exon1 of DSC1, therefore,
we could not analyse the methylation status of DSC1 in lung
cancer cells. We found that DSC2 and DSC3 were highly
methylated in four cell lines where restoration of mRNA
expression was detected by demethylation tests. As expected,
in normal control HBEC, neither DSC2 nor DSC3 DNA was
methylated.
Table 1 Study cohort
No. of patients




















ADC, adenocarcinoma; LCLC, large-cell lung carcinoma; SCLC, small-cell lung carcinoma;
SCC, squamous cell carcinoma.
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Protein expression of DSCs in primary lung tumours
Immunohistochemistry showed that DSC1-3 proteins were
mainly localised in membrane.
As shown in table 3, 47 cases (23.6%) exhibited expression of
DSC1. A reverse association between DSC1 expression and
tumour differentiation was found: high-grade tumours showed
significantly decreased expression of DSC1 (p=0.017, table 3).
However, the expression of DSC1 did not differ significantly by
other clinicopathological parameters. DSC2 and DSC3 were
expressed in 68.3% and 31.7% of primary lung tumours, respect-
ively. Additionally, DSC3 seemed to be a marker to distinguish
SCC from ADC, since SCC showed significantly more positive
staining of DSC3 compared with ADC (p<0.001, table 3).
Examples of DSC1-3 protein expression in primary SCC of lung
are shown in figure 2. In bronchial epithelial cells of normal
bronchus, DSC1-3 staining was not visible (figure 2E–G).
From follow-up data we found that the median survival time
for DSC1, DSC2, DSC3 positive and negative patients were
1158 and 787 days, 948 and 835 days, as well as 1218 and
744 days, respectively. Kaplan–Meier survival analysis revealed
that downregulation of DSC1 and DSC3 was significantly
linked to shorter overall survival (p=0.045 for DSC1; p=0.007
for DSC3, figure 3A,C). However, the expression of DSC2 was
not correlated with clinical outcome (p=0.544, figure 3B).
Cox hazard analyses of lung cancer patient prognosis
The correlation between DSC1-3 expression and clinical
outcome was analysed in a multivariable Cox proportional
hazard regression model to discover optimal independent prog-
nostic factors. The results are shown in table 4. DSC1
(HR=1.682, p=0.037) and DSC3 (HR=2.004, p=0.004) were
the optimal independent prognostic factors in the final regres-
sion model, but not DSC2 (HR=0.759, p=0.229).
DISCUSSION
Desmosomes, together with adherens junctions, represent the
major adhesive cell junctions of epithelial cells.18 Desmosomal
components are downregulated in certain types of carcinoma,
suggesting their possible role in tumour suppression.19–22
In this study, we found that the expression of DSC1-3 was
significantly downregulated compared with normal control
cells. The molecular mechanism responsible for the altered
DSCs expression in lung cancer has not yet been well eluci-
dated. So far, no genetic alterations of DSCs have been found.
Except for the detailed description of methylation patterns of
DSC3 in breast and colon cancer,13 14 no epigenetic regulation
of DSCs has been reported in any other tumour entities. In our
study, demethylation tests of DSCs by using the pharmaceut-
ical agent DAC restored the expression of DSCs in four out of
seven lung cancer cell lines. In line with this, methylation was
detected in 31 CpG sites and 20 CpG sites of exon 1 in DSC2
and DSC3 respectively. These results suggested that DNA
hypermethylation is at least partially responsible for the gene
silencing of DSC2 and DSC3 in lung cancer cells.
It has been suggested that desmosomal components may
contribute to the differentiation of human endometrial carcin-
oma.23 Besides, Monica et al24 and Tsuta et al25 reported that
DSC3 was a marker for poorly differentiated SCC and also for
squamous differentiation in undifferentiated large cell lung car-
cinoma (LCLC). Consistent with these results, we observed
that lose of DSC1 expression was associated with poor differen-
tiation in primary lung tumours.
Despite extensive study, there are few clinically useful immu-
nohistochemical markers for lung cancer diagnosis and progno-
sis.26 Late diagnosis is a fundamental obstacle to improving
lung cancer outcomes.27–29 In our study, we could only divide
the primary tumours into two major subgroups of SCC and
ADC for statistical analysis, since the sample size of small cell
lung carcinoma (SCLC) and LCLC was too small to be further
evaluated. In line with the report from Boelens et al,30 we
found that DSC1-3 expression was not visible in normal bron-
chial epithelial cells, indicating that DSC1-3 may be upregu-
lated in primary SCC of lung, and additionally, DSC3 seemed
to be a marker to distinguish SCC from ADC, since 45.3% of
Figure 1 A: DSCs expression
analysis in lung cancer cell lines and
human bronchial epithelial cells
(HBEC). DSCs mRNA expression was
analysed by RT-PCR, showing that
DSC1-3 was expressed in HBEC. In
lung cancer cell lines, DSC1 was found
to be expressed in H23, H2170, H322,
as well as H226, and DSC3 was
merely expressed in H226. Unlike
DSC1 and DSC3, DSC2 was expressed
in the most of the cell lines tested
except for CPC-N and COLO677.
Glyceraldehyde-3-phosphate
dehydrogenase was used as loading
control. B: Demethylation tests in lung
cancer cell lines. RT-PCR showed that
after treatment with different
concentrations of deoxycytidine for
96 h, DSCs mRNA expression was
heterogeneously upregulated in four
out of seven cell lines. * indicates
non-small cell lung carcinoma cell
lines.
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SCCs exhibited expression of DSC3, while less than 8% of
ADCs were DSC3 positive (table 3). This result was also in
good agreement with the expression pattern of DSC3 in non-
small cell lung carcinoma (NSCLC) cell lines, since DSC3
mRNA was only expressed in a SCC cell line H226, while lost
in all the ADC cell lines (figure 1A). Compared with the study
by Tsuta et al which showed that 100% of SCC samples were
positive for DSC3 staining, our positive rate was lower. The dis-
crepancy is probably due to different antibodies, technologies
and the staining evaluation. So far, only p63 and CK5/6 are
widely used as diagnostic markers for SCC of lung, while
thyroid transcription factor-1 (TTF-1) together with CK7 is
considered as a marker for lung ADC.31–34 Based on the expres-
sion of DSC3 alone, it might be not sufficient to make a diag-
nosis for SCC of lung, however, we hope that in combination
with the classic markers, DSC3 may contribute to subclassifica-
tion of NSCLC.
Desmosomal proteins have also been considered as prognostic
markers in various cancer types. For example, downregulation
of desmoplakin expression provides prognostic information in
human oropharyngeal cancer.21 Decreased DSG3 expression
was associated with poor prognosis in lung cancer.11 Recently,
Table 3 Correlation between DSCs expression and clinicopathologic parameters
DSC1 DSC2 DSC3
Clinicopathological parameters (−) (+) p Value (−) (+) p Value (−) (+) p Value
T stage
T1 31 (15.6) 15 (7.5) 0.895* 10 (5.0) 36 (18.1) 0.570* 35 (17.6) 11 (5.5) 0.157
T2 86 (43.2) 20 (10.1) 36 (18.1) 70 (35.2) 72 (36.2) 34 (17.1)
T3 23 (11.6) 4 (2.0) 10 (5.0) 17 (8.5) 15 (7.5) 12 (6.0)
T4 9 (4.5) 6 (3.0) 3 (1.5) 12 (6.0) 9 (4.5) 6 (3.0)
N stage
N0 72 (36.2) 20 (10.1) 0.993* 31 (15.6) 61 (30.7) 0.613* 64 (32.2) 28 (14.1) 0.640*
N1 44 (22.1) 8 (4.0) 13 (6.5) 39 (19.6) 31 (15.6) 21 (10.6)
N2 18 (9.0) 9 (4.5) 9 (4.5) 18 (9.0) 20 (10.1) 7 (3.5)
N3 2 (1.0) 0 (0) 2 (1.0) 0 (0) 2 (1.0) 0 (0)
Tumor differentiation
G1 66 (34.6) 13 (6.8) 0.017 27 (14.1) 52 (27.2) 0.182 47 (24.6) 32 (16.8) 0.086
G2 51 (26.7) 16 (8.4) 21 (11.0) 46 (24.1) 48 (25.1) 19 (9.9)
G3 29 (15.2) 16 (8.4) 10 (5.2) 35 (18.3) 33 (17.3) 12 (6.3)
Histology
SCC 105 (52.8) 23 (11.6) 0.072 38 (19.1) 90 (45.2) 0.771 70 (35.2) 58 (29.1) <0.001*
ADC 39 (20.4) 24 (12.6) 20 (10.1) 43 (21.6) 58 (29.1) 5 (2.5)
Note: the values in parenthesis are present in percentage.
*Fisher’ exact test.
ADC, adenocarcinoma; SCC, squamous cell carcinoma.
Figure 2 Examples of DSC1-3 protein expression in primary squamous cell carcinoma of lung and bronchial epithelial cells of normal bronchus.
DSC1-3 proteins were mainly localised in membrane. A: DSC1 positive staining; B: DSC2 positive staining; C: DSC3 moderately positive; D: DSC3
strongly positive. E-G: DSC1-3 negative staining in normal bronchial epithelial cells. Image with 20×magnification of the corresponding case is
showed in the inset. This figure is only reproduced in colour in the online version.
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we reported that methylation of DSC3 DNA is a prognostic
marker in human colorectal cancer.13 In this study, we found
that reduced expression of DSC1 and DSC3 was associated
with an unfavourable prognosis in lung cancer. Like DSG3,
DSC1 and 3 seem to be a potential prognostic marker in lung
cancer.
In summary, our data showed that DSC1 may be a marker
for tumour differentiation, DSC3 protein expression may have
diagnostic value for subclassification of NSCLC into SCC and
ADC; moreover, patients with reduced DSC1 and DSC3 expres-
sion had poor prognosis. Further studies are needed to explore
the functional role of DSCs in lung carcinogenesis.
Take home messages
▸ Epigenetic regulation is involved in the downregulation of
DSC1-3 in lung cancer cells.
▸ We propose novel diagnostic marker DSC3 in distinguishing
lung SCC from adenocarcinoma.
▸ Additionally, DSC1 and DSC3 were thought to be novel
prognostic markers for patients with lung cancer.
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